Immune-checkpoint inhibitors in platinum-resistant ovarian cancer

Alice Indini, Olga Nigro, Csongor György Lengyel, Michele Ghidini, Angelica Petrillo, Salvatore Lopez, Francesco Raspagliesi, Dario Trapani, Shelize Khakoo, Giorgio Bogani

Research output: Contribution to journalReview articlepeer-review


Platinum-resistant ovarian cancer (OC) has limited treatment options and is associated with a poor prognosis. There appears to be an overlap between molecular mechanisms responsible for platinum resistance and immunogenicity in OC. Immunotherapy with single agent checkpoint inhibitors has been evaluated in a few clinical trials with disappointing results. This has prompted exploration of immunotherapy combination strategies with chemotherapy, anti-angiogenics, poly (ADP-ribose) polymerase (PARP) inhibitors and other targeted agents. The role of immunother-apy in the treatment of platinum-resistant OC remains undefined. The aim of this review is to describe the immunobiology of OC and likely benefit from immunotherapy, discuss clinical trial data and biomarkers that warrant further exploration, as well as provide an overview of future drug development strategies.

Original languageEnglish
Article number1663
Issue number7
Publication statusPublished - Apr 1 2021


  • Immune checkpoint inhibitors
  • Immunotherapy
  • New drugs
  • Ovarian cancer
  • Platinum-resistance

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Immune-checkpoint inhibitors in platinum-resistant ovarian cancer'. Together they form a unique fingerprint.

Cite this